|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Armstrong DK and Brady MF: Intraperitoneal
therapy for ovarian cancer: a treatment ready for prime time. J
Clin Oncol. 24:4531–4533. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gore M, du Bois A and Vergote I:
Intraperitoneal chemotherapy in ovarian cancer remains
experimental. J Clin Oncol. 24:4528–4530. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bao B, Ahmad A, Azmi AS, Ali S and Sarkar
FH: Overview of cancer stem cells (CSCs) and mechanisms of their
regulation: implications for cancer therapy. Curr Protoc Pharmacol.
14:Unit. 14–25. 2013.
|
|
5
|
Marusyk A and Polyak K: Tumor
heterogeneity: causes and consequences. Biochim Biophys Acta.
1805:105–117. 2010.PubMed/NCBI
|
|
6
|
Glaysher S, Gabriel FG, Johnson P, et al:
Molecular basis of chemosensitivity of platinum pre-treated ovarian
cancer to chemotherapy. Br J Cancer. 103:656–662. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meinhold-Heerlein I and Hauptmann S: The
heterogeneity of ovarian cancer. Arch Gynecol Obstet. 289:237–239.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Glaysher S and Cree IA: Cell sensitivity
assays: the ATP-based tumor chemosensitivity assay. Methods Mol
Biol. 731:247–257. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kurbacher CM and Cree IA: Chemosensitivity
testing using microplate adenosine triphosphate-based luminescence
measurements. Methods Mol Med. 110:101–120. 2005.PubMed/NCBI
|
|
10
|
Qi CJ, Ning YL, Zhu YL, et al: In vitro
chemosensitivity in breast cancer using ATP-tumor chemosensitivity
assay. Arch Pharm Res. 32:1737–1742. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sevin BU, Peng ZL, Perras JP, et al:
Application of an ATP-bioluminescence assay in human tumor
chemosensitivity testing. Gynecol Oncol. 31:191–204. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Konecny G, Crohns C, Pegram M, et al:
Correlation of drug response with the ATP tumor chemosensitivity
assay in primary FIGO stage III ovarian cancer. Gynecol Oncol.
77:258–263. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Neubauer H, Stefanova M, Solomayer E, et
al: Predicting resistance to platinum-containing chemotherapy with
the ATP tumor chemosensitivity assay in primary ovarian cancer.
Anticancer Res. 28:949–955. 2008.PubMed/NCBI
|
|
14
|
Zhao D, Zhang W, Li XG, et al: Predicting
clinical chemo-sensitivity of primary ovarian cancer using
adenosine triphosphate-tumor chemosensitivity assay combined with
detection of drug resistance genes. Zhonghua Fu Chan Ke Za Zhi.
46:193–198. 2011.[(In Chinese)]. PubMed/NCBI
|
|
15
|
Cree IA, Kurbacher CM, Lamont A, et al: A
prospective randomized controlled trial of tumour chemosensitivity
assay directed chemotherapy versus physician's choice in patients
with recurrent platinum-resistant ovarian cancer. Anticancer Drugs.
18:1093–1101. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sharma S, Neale MH, Di Nicolantonio F, et
al: Outcome of ATP-based tumor chemosensitivity assay directed
chemotherapy in heavily pre-treated recurrent ovarian carcinoma.
BMC Cancer. 3:192003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cree IA, Kurbacher CM, Untch M, et al:
Correlation of clinical response to chemotherapy in breast cancer
with ex vivo chemosensitivity. Anticancer Drugs. 7:630–635. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Andreotti PE, Cree IA, Kurbacher CM, et
al: Chemosensitivity testing of human tumors using a microplate
adenosine triphosphate luminescence assay: clinical correlation for
cisplatin resistance of ovarian carcinoma. Cancer Res.
55:5276–5282. 1995.PubMed/NCBI
|
|
19
|
Ling ZQ, Qi CJ, Lu XX, et al:
Heterogeneity of chemosensitivity in esophageal cancer using
ATP-tumor chemosensitivity assay. Acta Pharmacol Sin. 33:401–406.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
National Comprehensive Cancer Network:
Ovarian cancer including fallopian tube cancer and primary
peritoneal cancer. Version 1. 2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarianAccessed.
February 13–2015.
|
|
21
|
Fung-Kee-Fung M, Oliver T, Elit L, et al:
Optimal chemotherapy treatment for women with recurrent ovarian
cancer. Curr Oncol. 14:195–208. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Parmar MK, Ledermann JA, Colombo N, et al:
Paclitaxel plus platinum-based chemotherapy versus conventional
platinum-based chemotherapy in women with relapsed ovarian cancer:
the ICON4/AGO-OVAR-2.2 trial. Lancet. 361:2099–2106. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gynecologic Oncology Group; Markman M,
Blessing J, Rubin SC, Connor J, Hanjani P and Waggoner S: Phase II
trial of weekly paclitaxel (80 mg/m2) in platinum and
paclitaxel-resistant ovarian and primary peritoneal cancers: a
Gynecologic Oncology Group study. Gynecol Oncol. 101:436–440. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sharma R, Graham J, Mitchell H, Brooks A,
Blagden S and Gabra H: Extended weekly dose-dense
paclitaxel/carboplatin is feasible and active in heavily
pre-treated platinum-resistant recurrent ovarian cancer. Br J
Cancer. 100:707–712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kyrgiou M, Salanti G, Pavlidis N,
Paraskevaidis E and Ioannidis JP: Survival benefits with diverse
chemotherapy regimens for ovarian cancer: meta-analysis of multiple
treatments. J Natl Cancer Inst. 98:1655–1663. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vergote I: Prognostic factors in stage I
ovarian carcinoma. Verh K Acad Geneeskd Belg. 63:257–271.
2001.PubMed/NCBI
|
|
27
|
Gadducci A, Cosio S, Zola P, Sostegni B,
Fuso L and Sartori E: Prognostic factors and clinical outcome of
patients with recurrent early-stage epithelial ovarian cancer: an
Italian multicenter retrospective study. Int J Gynecol Cancer.
23:461–468. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Seidman JD, Yemelyanova AV, Khedmati F, et
al: Prognostic factors for stage I ovarian carcinoma. Int J Gynecol
Pathol. 29:1–7. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chan JK, Tian C, Monk BJ, et al:
Prognostic factors for high-risk early-stage epithelial ovarian
cancer: a Gynecologic Oncology Group study. Cancer. 112:2202–2210.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tropé C, Kaern J, Hogberg T, et al:
Randomized study on adjuvant chemotherapy in stage I high-risk
ovarian cancer with evaluation of DNA-ploidy as prognostic
instrument. Ann Oncol. 11:281–288. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bertelsen K, Hølund B, Andersen JE,
Nielsen K, Strøyer I and Ladehoff P: Prognostic factors and
adjuvant treatment in early epithelial ovarian cancer. Int J
Gynecol Cancer. 3:211–218. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Swart AC: on behalf of ICON collaborators:
Long-term follow-up of women enrolled in a randomized trial of
adjuvant chemotherapy for early stage ovarian cancer (ICON1). J
Clin Oncol, ASCO Annual Meeting Proceedings Part I 25 (June 20
Supplement). 55092007.
|
|
33
|
Chan JK, Tian C, Teoh D, et al: Survival
after recurrence is poor for women with early-stage high-risk
ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol.
116:307–311. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sinilnikova OM, Mazoyer S, Bonnardel C, et
al: BRCA1 and BRCA2 mutations in breast and ovarian cancer
syndrome: reflection on the Creighton University historical series
of high risk families. Fam Cancer. 5:15–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Daly MB, Axilbund JE, Buys S, et al:
Genetic/familial high-risk assessment: breast and ovarian. J Natl
Compr Canc Netw. 8:562–594. 2010.PubMed/NCBI
|
